<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35538553</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1752-1947</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medical case reports</Title>
          <ISOAbbreviation>J Med Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.</ArticleTitle>
        <Pagination>
          <StartPage>195</StartPage>
          <MedlinePgn>195</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">195</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-022-03375-x</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Teprotumumab is a novel treatment that reduces inflammation and symptoms caused by thyroid eye disease. There are limited data on teprotumumab's effect on intraocular pressure.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We report nine patients diagnosed with thyroid eye disease whose intraocular pressure decreased during teprotumumab treatment for 8 weeks: patient 1, a 67-year-old Hispanic woman; patient 2, an 86-year-old African-American man; patient 3, a 71-year-old Caucasian woman; patient 4, a 72-year-old Hispanic woman; patient 5, a 65-year-old Caucasian woman; patient 6, a 54-year-old Caucasian man; patient 7, a 54-year-old Asian man; patient 8, a 31-year-old Asian woman; patient 9, a 60-year-old Caucasian woman. The diagnosis of thyroid eye disease was based on increased redness, swelling, and excessive tearing; abnormal proptosis, lid retraction, and diplopia measurements were also taken during physical examination. Intraocular pressure in primary, lateral gaze, and upgaze was documented. There was significant (p = 0.0397) improvement of primary gaze eye pressure from pre-teprotumumab infusions (baseline) to completion of the treatment course.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Teprotumumab significantly decreased the intraocular pressure for patients during the duration of the study. Teprotumumab is a novel medication that is approved for the primary treatment of thyroid eye disease in both acute and chronic thyroid eye disease. Previous treatments used to treat thyroid eye disease include glucocorticoids, radiotherapy, or orbital decompression surgery; however, these treatments all have significant limitations. Teprotumumab is an effective noninvasive alternative for decreasing symptoms of thyroid eye disease and, as shown, also lowers intraocular pressure. However, teprotumumab should not be used as a substitute for glaucoma medications; its ability to lower intraocular pressure may be in addition to lowering periorbital pressure and retro-orbital pressure.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chu</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Southern California Eye Physicians and Surgeons, 1111 S. Fair Oaks Ave., Pasadena, CA, 91105, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sung</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Oculofacial and Orbital Surgery, 10861 Cherry St., #208, Los Alamitos, CA, 90720, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Oculofacial and Orbital Surgery, 10861 Cherry St., #208, Los Alamitos, CA, 90720, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Alice</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Oculofacial and Orbital Surgery, 10861 Cherry St., #208, Los Alamitos, CA, 90720, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-4278-6286</Identifier>
            <AffiliationInfo>
              <Affiliation>Southern California Eye Physicians and Surgeons, 1111 S. Fair Oaks Ave., Pasadena, CA, 91105, USA. jsongmd@drsongvision.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Med Case Rep</MedlineTA>
        <NlmUniqueID>101293382</NlmUniqueID>
        <ISSNLinking>1752-1947</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Y64GQ0KC0A</RegistryNumber>
          <NameOfSubstance UI="C551399">teprotumumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005094" MajorTopicYN="Y">Exophthalmos</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="Y">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007429" MajorTopicYN="N">Intraocular Pressure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Intraocular pressure</Keyword>
        <Keyword MajorTopicYN="N">Lateral gaze</Keyword>
        <Keyword MajorTopicYN="N">Primary gaze</Keyword>
        <Keyword MajorTopicYN="N">Teprotumumab</Keyword>
        <Keyword MajorTopicYN="N">Thyroid eye disease</Keyword>
        <Keyword MajorTopicYN="N">Upgaze</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>23</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35538553</ArticleId>
        <ArticleId IdType="pmc">PMC9087984</ArticleId>
        <ArticleId IdType="doi">10.1186/s13256-022-03375-x</ArticleId>
        <ArticleId IdType="pii">10.1186/s13256-022-03375-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Douglas RS, Kahaly GJ, Patel A, et al.  Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020 doi: 10.1056/NEJMoa1910434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910434</ArticleId>
            <ArticleId IdType="pubmed">32579811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–738. doi: 10.1056/NEJMra0905750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra0905750</ArticleId>
            <ArticleId IdType="pmc">PMC3902010</ArticleId>
            <ArticleId IdType="pubmed">20181974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375(16):1552–1565. doi: 10.1056/NEJMra1510030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1510030</ArticleId>
            <ArticleId IdType="pubmed">27797318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170(12):6348–6354. doi: 10.4049/jimmunol.170.12.6348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.170.12.6348</ArticleId>
            <ArticleId IdType="pubmed">12794168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahn R. Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res. 2015;47(10):773–778. doi: 10.1055/s-0035-1555762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0035-1555762</ArticleId>
            <ArticleId IdType="pubmed">26361262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verity DH, Rose GE. Acute thyroid eye disease (TED): principles of medical and surgical management. Eye. 2013;27(3):308–319. doi: 10.1038/eye.2012.284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/eye.2012.284</ArticleId>
            <ArticleId IdType="pmc">PMC3597885</ArticleId>
            <ArticleId IdType="pubmed">23412559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Geest RJ, Sasim IV, Koppeschaar HPF, et al.  Methylprednisolone pulse therapy for patients with moderately severe Graves’ orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008;158(2):229–237. doi: 10.1530/EJE-07-0558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-07-0558</ArticleId>
            <ArticleId IdType="pubmed">18230831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danesh-Meyer HV, Savino PJ, Deramo V, Sergott RC, Smith AF. Intraocular pressure changes after treatment for Graves’ orbitopathy. Ophthalmology. 2001;108(1):145–150. doi: 10.1016/S0161-6420(00)00477-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0161-6420(00)00477-2</ArticleId>
            <ArticleId IdType="pubmed">11150280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spierer A, Eisenstein Z. The role of increased intraocular pressure on upgaze in the assessment of Graves ophthalmopathy. Ophthalmology. 1991;98(10):1491–1494. doi: 10.1016/S0161-6420(91)32100-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0161-6420(91)32100-6</ArticleId>
            <ArticleId IdType="pubmed">1961632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nassr MA, Morris CL, Netland PA, Karcioglu ZA. Intraocular pressure change in orbital disease. Surv Ophthalmol. 2009;54(5):519–544. doi: 10.1016/j.survophthal.2009.02.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.survophthal.2009.02.023</ArticleId>
            <ArticleId IdType="pubmed">19682621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ting M, Ezra DG. Teprotumumab: a disease modifying treatment for Graves’ orbitopathy. Thyroid Res. 2020 doi: 10.1186/s13044-020-00086-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13044-020-00086-7</ArticleId>
            <ArticleId IdType="pmc">PMC7334856</ArticleId>
            <ArticleId IdType="pubmed">32636936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Patzek S. Teprotumumab for active thyroid eye disease. N Engl J Med. 2020;382(20):1958–1959. doi: 10.1056/NEJMc2002754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2002754</ArticleId>
            <ArticleId IdType="pubmed">32402170</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
